Pharming Group N.V. (NASDAQ:PHAR) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET
Company Participants
Sijmen de Vries - Executive Director and Chief Executive Officer
Anurag Relan - Chief Medical Officer
Stephen Toor - Chief Commercial Officer
Jeroen Wakkerman - Chief Financial Officer
Conference Call Participants
Christian Glennie - Stifel
Joseph Pantginis - H.C. Wainwright
Natalia Webster - RBC Capital Markets
Sijmen de Vries
Thank you very much, Adam. Good morning or good afternoon, ladies and gentlemen. Welcome to our Second Quarter and First Half 2023 Financial Results Call.
Next slide, please. I’m here with my three colleagues, Dr. Anurag Relan, our Chief Medical Officer; Stephen Toor, our Chief Commercial Officer; and Jeroen Wakkerman, our Chief Financial Officer, to take you through the highlights of these results and, of course, to answer all your questions that you may have afterwards.
But before I do that, of course, I would like to point you to the next slide that says something about forward-looking statements because we will be making some forward-looking statements, of course, today, that are based upon our current plans, belief, market circumstances, et cetera, that may, of course, change towards the future.
And then without further ado, I would like to move on to 2 slides ahead and basically share with you some of the excitement over the last six months that we had, of course, and we had a very busy six months and indeed made a lot of progress.
And – but first and foremost, we’re, of course, very, very pleased to see that RUCONEST did it again, so to say, 20% growth over the second quarter results versus the first quarter is, of course, a very spectacular recovery from what was a one-off weakness in the first quarter.
And that means that if you look at it, we’re very confident that we can actually continue to be on track for the low single-digit growth for the entire year. And we say that based upon the leading indicators that all point in the right direction. Of course, Stephen, will talk a little bit more about that later in his part of the presentation.
Now that significant cash flows, of course, that RUCONEST has been generating over the years not only helped us to, back in the days of 2019, in license Joenja from Novartis but also helped us, of course, to finance the development of Novartis and of course – of Joenja, and of course, to actually prepare for the successful U.S. launch, and that’s exactly what happened.